[Infographics] Darolutamide + ADT in mHSPC: rPFS, time to mCRPC, OS & QoL benefits
11 Nov 2026
MIMS Editorial Team
MIMS Editorial Team
Darolutamide + ADT in patients with mHSPC provides a clinically significant delay in radiographic progression with minimal treatment burden.1
The clinically meaningful delays in pain progression and time to deterioration of overall well-being vs placebo + ADT support consideration of darolutamide + ADT as a SoC treatment option in patients with mHSPC.2
ARASEC provides further evidence for the efficacy and safety of darolutamide + ADT in mHSPC, reinforcing findings from ARANOTE.3
![[Infographics] Darolutamide + ADT in mHSPC: rPFS, time to mCRPC, OS & QoL benefits](_content/MIMS.Specialty.Components/assets/image_onerror.webp)